International Stem Cell Corporation (OTCBB:ISCO),
www.intlstemcell.com,
a California-based biotechnology company focused on therapeutic and
research products, announced today that Charles J. Casamento was elected
to the Board of Directors, on June 21, 2010.
Mr. Casamento is currently Executive Director and Principal of The Sage
Group, a healthcare advisory group specializing in mergers,
acquisitions, and partnerships between biotechnology companies and
pharmaceutical companies. During his career, Mr. Casamento has served as
a director on the boards of eight public biotechnology/pharmaceutical
companies. He was the president and CEO of Osteologix, Inc., a public
biopharmaceutical company developing products for treating osteoporosis,
from 2004 through 2007. From 1999 through 2004, he served as chairman of
the board, president and CEO of Questcor Pharmaceuticals, Inc. Mr.
Casamento formerly served as RiboGene, Inc.'s president, CEO and
chairman of the board from 1993 through 1999 until it merged with Cypros
to form Questcor. He was co-founder, president and CEO of Interneuron
Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989
until 1993. Mr. Casamento has also held senior management positions at
Genzyme Corporation, where he was senior vice president, pharmaceuticals
and biochemicals; American Hospital Supply, where he was vice president
of business development and strategic planning for the Critical Care
Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr.
Casamento also serves on the Boards of Directors of CORTEX
Pharmaceuticals, SuperGen, Inc. and VIVUS, Inc. He holds a bachelor's
degree in Pharmacy from Fordham University and an M.B.A. from Iona
College and was originally licensed to practice pharmacy in the states
of New York and New Jersey.
'Mr. Casamento is a vital addition to our Board and brings to
International Stem Cell Corporation expertise in areas that will help
guide our company through growth, including corporate governance,
business development, strategic planning, financing, mergers and
acquisitions, product development, clinical trials and corporate and
research and development collaboration activities,' said Kenneth
Aldrich, Chairman.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos. ISCO
scientists have created the first parthenogenic, homozygous stem cell
line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing sexes, ages and racial groups. This offers the potential to
create the first true stem cell bank, UniStemCell(TM), while
avoiding the ethical issue of using fertilized eggs. ISCO also produces
and markets specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology. More
information is available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING
Statements pertaining to anticipated technological developments and
therapeutic applications, and other opportunities for the company and
its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as 'will,' 'believes,' 'plans,' 'anticipates,'
'expects,' 'estimates') should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Brian
Lundstrom, President 760-640-6383 bl@intlstemcell.com |